LT2704742T - Anti-alfa4beta7 antikūno kompozicija - Google Patents

Anti-alfa4beta7 antikūno kompozicija

Info

Publication number
LT2704742T
LT2704742T LTEP12722973.0T LT12722973T LT2704742T LT 2704742 T LT2704742 T LT 2704742T LT 12722973 T LT12722973 T LT 12722973T LT 2704742 T LT2704742 T LT 2704742T
Authority
LT
Lithuania
Prior art keywords
antibody
formulation
Prior art date
Application number
LTEP12722973.0T
Other languages
English (en)
Inventor
Willow Diluzio
Phuong M. Nguyen
Csanad M. Varga
Vaithianathan Palaniappan
Jason Brown
Irving H. FOX
Catherine SCHOLZ
Erica Helen Jenkins
Maria Rosario
Original Assignee
Millennium Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2704742(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals, Inc. filed Critical Millennium Pharmaceuticals, Inc.
Publication of LT2704742T publication Critical patent/LT2704742T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
LTEP12722973.0T 2011-05-02 2012-05-02 Anti-alfa4beta7 antikūno kompozicija LT2704742T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161481522P 2011-05-02 2011-05-02
US201161544054P 2011-10-06 2011-10-06
PCT/US2012/036069 WO2012151247A2 (en) 2011-05-02 2012-05-02 FORMULATION FOR ANTI-α4β7 ANTIBODY

Publications (1)

Publication Number Publication Date
LT2704742T true LT2704742T (lt) 2017-10-25

Family

ID=46147702

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12722973.0T LT2704742T (lt) 2011-05-02 2012-05-02 Anti-alfa4beta7 antikūno kompozicija

Country Status (37)

Country Link
US (6) US10040855B2 (lt)
EP (2) EP2704742B1 (lt)
JP (5) JP6190359B2 (lt)
KR (7) KR102493433B1 (lt)
CN (4) CN107998388B (lt)
AR (1) AR086238A1 (lt)
AU (5) AU2012250872B2 (lt)
CA (2) CA3051418C (lt)
CL (3) CL2013003145A1 (lt)
CO (1) CO6801648A2 (lt)
CR (1) CR20130556A (lt)
CY (1) CY1119436T1 (lt)
DK (1) DK2704742T3 (lt)
DO (1) DOP2013000252A (lt)
EA (1) EA032625B1 (lt)
EC (1) ECSP22046340A (lt)
ES (1) ES2646717T3 (lt)
GE (1) GEP20186866B (lt)
HK (1) HK1253911A1 (lt)
HR (1) HRP20171457T1 (lt)
HU (1) HUE036664T2 (lt)
IL (6) IL305583A (lt)
LT (1) LT2704742T (lt)
ME (1) ME02858B (lt)
MX (4) MX354101B (lt)
MY (1) MY188820A (lt)
PE (1) PE20141672A1 (lt)
PH (2) PH12018502221A1 (lt)
PL (1) PL2704742T3 (lt)
PT (1) PT2704742T (lt)
RS (1) RS56429B1 (lt)
SG (1) SG194730A1 (lt)
SI (1) SI2704742T1 (lt)
TW (4) TWI799757B (lt)
UY (1) UY34054A (lt)
WO (1) WO2012151247A2 (lt)
ZA (2) ZA201308168B (lt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2521568B1 (en) 2010-01-06 2018-07-25 Dyax Corp. Plasma kallikrein binding proteins
PL2624865T3 (pl) * 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
IL310186A (en) 2011-01-06 2024-03-01 Takeda Pharmaceuticals Co KALLIKREIN PLASMA BINDING PROTEINS
CN107998388B (zh) 2011-05-02 2023-07-14 千禧制药公司 抗α4β7抗体的制剂
EP3130921B1 (en) 2011-07-06 2018-09-12 Nestec S.A. Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9764093B2 (en) * 2012-11-30 2017-09-19 Sio2 Medical Products, Inc. Controlling the uniformity of PECVD deposition
CN105051068A (zh) 2013-03-15 2015-11-11 戴埃克斯有限公司 抗血浆激肽释放酶抗体
KR20220129671A (ko) * 2013-07-05 2022-09-23 인테그라 메디컬 인코포레이티드 구강 조성물
AU2014354384B2 (en) * 2013-11-29 2018-11-08 Ares Trading S.A. A liquid formulation of a fusion protein comprising TNFR and Fc region
IL292655B2 (en) 2014-10-06 2024-03-01 Chemocentryx Inc CCR9 chemokine receptor inhibitor for use in a method for treating or reducing the development of inflammatory bowel diseases
EP3581585A1 (en) 2014-11-26 2019-12-18 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
HUE052280T2 (hu) * 2014-12-03 2021-04-28 Csl Behring Ag Immunoglobulinokat tartalmazó megnövelt stabilitású gyógyszerészeti termék
EP3536705A1 (en) * 2014-12-05 2019-09-11 Société des Produits Nestlé S.A. Isolated soluble alpha-4 integrin, beta-7 integrin and alpha-4/beta-7 heterodimer integrin
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
CA2979713A1 (en) * 2015-03-30 2016-10-06 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
AU2016380988B2 (en) * 2015-12-30 2022-07-21 Genentech, Inc. Formulations with reduced degradation of polysorbate
USD866757S1 (en) 2016-03-11 2019-11-12 Millennium Pharmaceuticals, Inc. Autoinjector
EP3430052A2 (en) 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
AU2017234010A1 (en) 2016-03-14 2018-09-27 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
JP7069032B2 (ja) 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
US10918716B2 (en) 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease
US11389533B2 (en) 2016-06-12 2022-07-19 Takeda Pharmaceutical Company Limited Method of treating inflammatory bowel disease
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
WO2018116198A1 (en) * 2016-12-23 2018-06-28 Serum Institute Of India Private Limited Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
CN108686204A (zh) * 2017-04-07 2018-10-23 浙江海正药业股份有限公司 包含组氨酸缓冲体系的英夫利西单抗组合物
CN110612120A (zh) 2017-04-28 2019-12-24 千禧制药公司 使用特异性于α4β7整联蛋白的抗体(维多珠单抗)治疗儿科病症的方法
EP3672994A4 (en) * 2017-08-25 2021-06-02 Omeros Corporation HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITIVE ANTIBODY FORMULATIONS, KITS, AND METHODS FOR TREATING PEOPLE WITH ATYPICAL HEMOLYTIC SYNDROME
AU2019251453A1 (en) * 2018-04-10 2020-11-26 Dr. Reddy’S Laboratories Limited Stable formulations of therapeutic antibody
SG11202009874QA (en) * 2018-04-10 2020-11-27 Dr Reddys Laboratories Ltd Antibody formulation
EP3773695A4 (en) * 2018-04-10 2021-12-22 Dr. Reddy's Laboratories Ltd. STABLE ANTIBODY FORMULATION
WO2020044204A1 (en) * 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Methods of preparing stable liquid therapeutic protein compositions
CN113474360A (zh) 2019-02-18 2021-10-01 伊莱利利公司 治疗性抗体制剂
EP3980119A4 (en) * 2019-06-10 2023-06-07 Takeda Pharmaceutical Company Limited METHODS FOR PURIFYING ANTIBODIES AND ASSOCIATED COMPOSITIONS
CN114746439A (zh) * 2019-10-11 2022-07-12 雷迪博士实验室有限公司 整合蛋白抗体的稳定制剂
IL300133A (en) * 2020-07-31 2023-03-01 Genentech Inc Anti-integrin antibody compositions in cell 7 and devices
EP4259192A1 (en) * 2020-12-09 2023-10-18 Dr. Reddy's Laboratories Limited Stable aqueous buffer free formulation of an integrin antibody
WO2022253994A1 (en) * 2021-06-04 2022-12-08 Polpharma Biologics S.A. Vedolizumab formulation
CN113813377A (zh) * 2021-09-07 2021-12-21 杭州远大生物制药有限公司 抗α4β7抗体制剂及其应用
WO2023126411A1 (en) 2021-12-27 2023-07-06 Polpharma Biologics S.A. Vedolizumab formulation
WO2023230620A1 (en) * 2022-05-27 2023-11-30 Sonnet BioTherapeutics, Inc. Il-12-albumin-binding domain fusion protein formulations and methods of use thereof

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
EP0303463B1 (en) 1987-08-11 1994-11-30 The Board Of Trustees Of The Leland Stanford Junior University Method to control leukocyte extravasation
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223392A (en) 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
WO1990007321A2 (en) 1988-12-23 1990-07-12 The Board Of Trustees Of The Leland Stanford Junior University Lymphocyte receptor homing sequences and their uses
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
IL95501A (en) 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CZ282603B6 (cs) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
US5665595A (en) 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
WO1993015764A1 (en) 1992-02-12 1993-08-19 Biogen, Inc. Treatment for inflammatory bowel disease
AU4390893A (en) 1992-05-21 1993-12-13 Center For Blood Research, Inc., The A novel receptor for alpha4 integrins and methods based thereon
WO1994012214A1 (en) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
WO1994013312A1 (en) 1992-12-15 1994-06-23 The Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
JPH08507680A (ja) 1993-01-12 1996-08-20 バイオジェン インコーポレイテッド 組換え抗ｖｌａ４抗体分子
DK0682529T4 (da) 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
US6017695A (en) 1993-03-26 2000-01-25 Becton Dickinson And Company Nucleic acids encoding human cell adhesion molecule
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
ES2424292T3 (es) 1994-01-25 2013-09-30 Biogen Idec Ma Inc. Anticuerpos humanizados contra la molécula de adhesión leucocitaria VLA-4
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5594120A (en) 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5624321A (en) 1994-12-23 1997-04-29 Snyder; Stephen D. Spring-actuated swing device
ES2290955T3 (es) 1995-02-10 2008-02-16 Millennium Pharmaceuticals, Inc. Adresinas vasculares de mucosas y sus usos.
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
ATE512163T1 (de) 2002-02-25 2011-06-15 Elan Pharm Inc Verabreichung von mitteln zur behandlung von entzündungen
NZ566263A (en) 2002-05-24 2009-09-25 Millennium Pharm Inc CCR9 inhibitors and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
EP1598074B1 (en) 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
ES2349779T5 (es) 2003-04-04 2013-11-26 Genentech, Inc. Formulaciones de anticuerpos y de proteínas a concentración elevada
PL1784426T3 (pl) 2004-09-03 2012-04-30 Genentech Inc Humanizowani antagoniści anty-beta7 i ich zastosowania
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
BRPI0608855A2 (pt) 2005-03-08 2010-02-02 Pharmacia & Upjohn Co Llc composições de anticorpo anti - madcam processo para a preparação das mesmas e uso de anticorpo anti - madcam
WO2007007159A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat uterine disorders
CA2629147A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
CN101426817B (zh) 2006-04-21 2013-07-10 诺华有限公司 拮抗性抗-cd40抗体药物组合物
EP2109480B1 (en) 2006-12-07 2017-06-28 The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin
TW200831133A (en) * 2006-12-11 2008-08-01 Hoffmann La Roche Mab Abeta lyophylized formulation
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
US9111016B2 (en) 2007-07-06 2015-08-18 Stereotaxis, Inc. Management of live remote medical display
AU2008334605B2 (en) * 2007-12-13 2013-07-18 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
SG10201400798VA (en) 2009-03-20 2014-07-30 Amgen Inc Alpha-4-Beta-7 Heterodimer Specific Antagonist Antibody
CN101533504A (zh) * 2009-04-27 2009-09-16 刘文祥 电子医务系统及其装置
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN107998388B (zh) 2011-05-02 2023-07-14 千禧制药公司 抗α4β7抗体的制剂

Also Published As

Publication number Publication date
AU2021225160B2 (en) 2023-12-21
TWI638661B (zh) 2018-10-21
KR102014512B1 (ko) 2019-08-26
US20180346578A1 (en) 2018-12-06
JP2019052191A (ja) 2019-04-04
SI2704742T1 (sl) 2017-12-29
UY34054A (es) 2012-11-30
IL272237B (en) 2022-05-01
CN107998388B (zh) 2023-07-14
JP6467457B2 (ja) 2019-02-13
MX354101B (es) 2018-02-13
EA201391613A8 (ru) 2016-05-31
IL305583A (en) 2023-10-01
AU2019216679A1 (en) 2019-09-05
KR102493433B1 (ko) 2023-01-27
IL229169B (en) 2020-06-30
PH12018502221A1 (en) 2019-10-28
CL2017000829A1 (es) 2017-12-29
ME02858B (me) 2018-04-20
AU2021225160A1 (en) 2021-09-30
ES2646717T3 (es) 2017-12-15
JP2017137353A (ja) 2017-08-10
AU2019216679B2 (en) 2021-09-23
JP2014515763A (ja) 2014-07-03
CN108969469A (zh) 2018-12-11
PE20141672A1 (es) 2014-11-26
CN103533959B (zh) 2018-06-05
JP6190359B2 (ja) 2017-08-30
CY1119436T1 (el) 2018-03-07
IL229169A0 (en) 2013-12-31
EP2704742A2 (en) 2014-03-12
IL290848A (en) 2022-04-01
CA2834900C (en) 2021-03-02
ZA201707310B (en) 2022-04-28
EA032625B1 (ru) 2019-06-28
KR102308938B1 (ko) 2021-10-01
EA201391613A1 (ru) 2014-07-30
WO2012151247A2 (en) 2012-11-08
KR20190100451A (ko) 2019-08-28
KR102136208B1 (ko) 2020-07-21
HUE036664T2 (hu) 2018-07-30
MX367097B (es) 2019-08-05
US20210340261A1 (en) 2021-11-04
CO6801648A2 (es) 2013-11-29
MX2019009244A (es) 2019-09-13
ECSP22046340A (es) 2022-07-29
DK2704742T3 (en) 2017-10-23
KR20170056713A (ko) 2017-05-23
KR101875155B1 (ko) 2018-07-09
KR20140145952A (ko) 2014-12-24
ZA201308168B (en) 2018-11-28
IL274846A (en) 2020-07-30
US20200377601A1 (en) 2020-12-03
EP3311834A1 (en) 2018-04-25
CL2020001579A1 (es) 2020-11-06
MX2013012725A (es) 2013-12-06
CA3051418C (en) 2021-05-18
US20180327497A1 (en) 2018-11-15
MY188820A (en) 2022-01-05
US20140341885A1 (en) 2014-11-20
CA3051418A1 (en) 2012-11-08
CN107998388A (zh) 2018-05-08
SG194730A1 (en) 2013-12-30
KR20230021758A (ko) 2023-02-14
TWI723339B (zh) 2021-04-01
PT2704742T (pt) 2017-11-15
JP6751450B2 (ja) 2020-09-02
TW202133878A (zh) 2021-09-16
JP2022132430A (ja) 2022-09-08
WO2012151247A3 (en) 2013-02-28
TWI698254B (zh) 2020-07-11
CN108969761A (zh) 2018-12-11
HK1253911A1 (zh) 2019-07-05
US11560434B2 (en) 2023-01-24
CA2834900A1 (en) 2012-11-08
AU2023274233A1 (en) 2023-12-21
JP7107997B2 (ja) 2022-07-27
PH12019501662A1 (en) 2021-03-15
IL290849A (en) 2022-04-01
KR20200088517A (ko) 2020-07-22
DOP2013000252A (es) 2013-12-31
AU2012250872A1 (en) 2013-11-21
JP2020180163A (ja) 2020-11-05
EP2704742B1 (en) 2017-07-12
BR112013028169A2 (pt) 2017-06-27
KR101884406B1 (ko) 2018-08-02
RS56429B1 (sr) 2018-01-31
MX2021008112A (es) 2022-06-02
KR20210120144A (ko) 2021-10-06
CR20130556A (es) 2014-03-05
AR086238A1 (es) 2013-11-27
AU2017204192A1 (en) 2017-07-13
TW201940195A (zh) 2019-10-16
CN103533959A (zh) 2014-01-22
TW201813665A (zh) 2018-04-16
CL2013003145A1 (es) 2014-07-25
KR20180080354A (ko) 2018-07-11
TWI799757B (zh) 2023-04-21
AU2017204192B2 (en) 2019-09-12
TW201300128A (zh) 2013-01-01
NZ617340A (en) 2015-12-24
GEP20186866B (en) 2018-06-25
AU2012250872B2 (en) 2017-07-13
KR102493433B9 (ko) 2023-09-01
PL2704742T3 (pl) 2018-01-31
US20230312727A1 (en) 2023-10-05
HRP20171457T1 (hr) 2017-11-03
IL272237A (en) 2020-02-27
TW202317193A (zh) 2023-05-01
US10040855B2 (en) 2018-08-07

Similar Documents

Publication Publication Date Title
HRP20171457T1 (hr) Formulacija protutijela protiv 4-7
IL275038A (en) Formulation for anti-antibody alpha 4 in cell 7
IL276234B (en) Antibody compositions
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
IL259826A (en) Anti-alphabetatisiar antibody
EP2694539A4 (en) POLYCLONAL ANTIBODY COMPOSITIONS
EP2769988A4 (en) ANTI-GAP43 ANTIBODY